# Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors

> **NCT07189377** · PHASE4 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 20 (estimated)

## Conditions studied

- Hepatitis B Virus (HBV)
- Lung Transplant Recipient

## Interventions

- **DRUG:** Entecavir
- **BIOLOGICAL:** HBIG
- **DEVICE:** EVLP UV Light Treatment

## Key facts

- **NCT ID:** NCT07189377
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-24
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07189377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07189377, "Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07189377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*